Food Allergy News and Research

What Are Your Options for Epinephrine Auto-Injectors?

Epinephrine is a lifesaving medicine for people with severe allergies. It is important to discuss with your doctor about what is the most appropriate prescription for your family. You may also need to find out which options your insurance provider prefers. This will affect your out-of-pocket costs. Each device has its own unique set of instructions. Understanding those differences is important so that you get the device you want and you know how to use it. Pharmacists must follow state and...

KFA Issues Parental Guidance Warning About New Peter Rabbit Film

The Asthma and Allergy Foundation of America (AAFA) cautions parents raising children with food allergies that some scenes in the newly-released “Peter Rabbit” film may be disturbing for young viewers with food allergies. In the film, a character with a known food allergy to blackberries is attacked with them. This leads to a severe allergic reaction known as anaphylaxis and the need to use a lifesaving injection of the drug epinephrine.

Q&A: What Does Omalizumab Mean for Oral Immunotherapy Treatment for Multiple Food Allergies?

Oral immunotherapy (OIT) is a proposed method to treat food allergy. It is currently in late-stage clinical trials (peanut specifically). It is expected to be approved by the U.S. Food and Drug Administration (FDA) soon. There have been many clinical trials for specific food OIT alone and with medicines, such as omalizumab, as reported in this study.

Omalizumab Makes Oral Immunotherapy Treatments More Effective

Combining a 16-week initial course of the medication omalizumab with oral immunotherapy (OIT) greatly improves the efficacy of OIT for children with allergies to multiple foods, new clinical trial findings show. After 36 weeks, more than 80 percent of children who received omalizumab and OIT could safely consume two-gram portions of at least two foods to which they were allergic, compared with only a third of children who received placebo and OIT.

First Epinephrine Auto-Injector for Infants and Small Children Will Be Available in 2018

kaléo today announced that the U.S. Food and Drug Administration (FDA) has approved its supplemental New Drug Application (sNDA) for AUVI-Q® (epinephrine injection, USP) 0.1 mg, the first and only epinephrine auto-injector (EAI) specifically designed for the treatment of life-threatening allergic reactions, including anaphylaxis, in infants and small children weighing 16.5 to 33 pounds (7.5 to 15 kilograms) who are at risk for or have a history of serious allergic reactions.

Schools Have Been Able to Treat Anaphylaxis More Than 2,000 Times Thanks to Epinephrine Donation Program

Mylan N.V.(NASDAQ, TASE: MYL) today announced its EpiPen4Schools® program has surpassed the one millionth epinephrine auto-injector donation through the program and that presented data at the American College of Allergy, Asthma and Immunology (ACAAI) 2017 Annual Scientific Meeting demonstrates the impact of and continued need for the program in U.S. schools. Epinephrine auto-injectors provided through the program have been used more than 2,000 times to treat anaphylaxis, a potentially life-threa

New Prevention Guidelines May Reduce Increasing Rates of Peanut Allergy in Children

Parents often worry about peanut allergies because the reaction to peanuts can be very severe. New research being presented at the American College of Allergy, Asthma and Immunology (ACAAI) Annual Scientific Meeting suggests that peanut allergy in children has increased 21 percent since 2010, and that nearly 2.5 percent of U.S. children may have an allergy to peanuts.

Many Pediatricians Are Not Sharing New Peanut Introduction Guidelines With Parents

Guidelines to help parents introduce peanut-containing products to infants to prevent peanut allergies aren’t being discussed. New research presented at the American College of Allergy, Asthma and Immunology (ACAAI) Annual Scientific Meeting shows pediatricians are not only not having the discussion, they’re not referring high-risk babies for testing prior to peanut introduction.

Peanut Allergy Patch Study Misses Its Main Goal in Third Phase

Kids With Food Allergies is sharing this press release from DBV Technologies to bring you the latest research news quickly. [Press Release] DBV Technologies Announces Topline Results of Phase III Clinical Trial in Peanut Allergic Patients Four to 11 Years of Age DBV Technologies (Euronext: DBV – ISIN: FR0010417345 - Nasdaq Stock Market: DBVT) today announced topline results from the PEPITES (Peanut EPIT Efficacy and Safety) Phase III trial evaluating the safety and efficacy of Viaskin Peanut...

Kids With Food Allergies
A Division of the Asthma and Allergy Foundation of America
4259 W Swamp Rd, Suite 408, Doylestown, PA 18902
Phone: 215.230.5394 | Fax: 215.340.7674
-->
×
×
×
×